Positive momentum for French biotech industry continues: Abivax announces positive Phase II results (HIV)

The positive momentum of French biotech companies continues: Paris-based biotech Abivax this week has announced the top line data from a phase IIa trial assessing ABX464-005, a HIV therapy. As part of the study, 9 patients were treated with the product (180 mg) for 28 days and 8 of them have already benefited from it. Abivax’s shares have soon reacted with a 8% rise today (Paris).  This is a particularly positive momentum in the fight against HIV– Janssen (JnJ) has recently obtained approval for Symtuza in Europe, while France-based Sanofi has announced it is developing antibodies able to kill 99% of HIV strains.

 

(Source: Abivax)